Pancreatic cancer
Pancreatic cancer is a malignant disease of the pancreas that includes pancreatic ductal adenocarcinoma and less common pancreatic malignancies.
Pancreatic cancer is a malignant disease of the pancreas that includes pancreatic ductal adenocarcinoma and less common pancreatic malignancies. It is studied as a biologically heterogeneous disease involving cancer cells and the tumor microenvironment, with research addressing molecular alterations such as KRAS, biomarkers, treatment sensitivity, and patient stratification. Recent work has evaluated multi-omics approaches, organoid models, bile biomarkers—including VEGF, PDGF-AA, IGF, and matrix metalloproteinases—and targeted fecal microbial signatures for diagnosis or prognostic assessment.
Clinical and translational research spans surgical management, stereotactic body radiotherapy, systemic treatment, and supportive care. Pancreatic cancer studies have examined drug-response testing with microencapsulated tumor organoids, radiotherapy planning methods designed to reduce respiratory-motion blurring, pancreaticoduodenectomy with portal-vein management, and the health-care burden associated with cachexia. Other investigations have assessed the association between GLP-1 receptor agonist use and incident pancreatic cancer, while computational biomarker models seek improved disease detection and individualized treatment selection.
Where the papers sit
9 papers from the last 6 months study pancreatic cancer directly · updated from PubMed 20 Oct 2026
Study type 0 clinical trials · 5 observational · 1 human data · 1 preclinical · 2 unclassified
Themes one subject
Those 9 are all about one subject.
-
Pancreatic Oncology
Work spans pancreatic cancer diagnosis, prognosis, treatment planning, and supportive care rather than a single therapeutic direction. Organoids and incomplete multi-omics support drug sensitivity testing and patient stratification, while bile and gut microbial biomarkers seek earlier or more specific detection. Clinical studies address surgical management, SBRT motion, cachexia-related costs, and medication-associated risk. The field remains broad, with no dominant approach linking these studies.
Papers
The 9 papers from the last 6 months that study pancreatic cancer directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Pancreatic Oncology (9)
- PMID 42015571
- Microencapsulated tumor organoids maintain drug sensitivity stratification. Lab on a chip · 5 Oct 2026 PMID 42831367
- Temporary Mesocaval Bypass During Pancreaticoduodenectomy for Pancreatic Cancer With Portal Vein Occlusion: A Case Report. Anticancer research · 1 Oct 2026 PMID 42823171
- Well-differentiated SMARCB1-deficient Pancreatic Malignancy With Indolent Liver Metastases. Anticancer research · 1 Oct 2026 PMID 42823145
- Association between cachexia-associated diagnoses, health care resource utilization, and costs in patients with pancreatic, lung, and colorectal cancers: A US insurance claims database analysis. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808542
- Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network. Journal of gastrointestinal cancer · 16 Sept 2026 PMID 42745130
- Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data. PLoS computational biology · 10 Sept 2026 PMID 42721202
- Quantitative evaluation of respiratory motion-induced blurring in expiratory-phase CBCT for pancreatic SBRT. Journal of applied clinical medical physics · 31 Jul 2026 PMID 42535485
- Disease-specific gut microbial signatures generate model-derived cancer probability scores through targeted fecal qPCR profiling. Bioscience, biotechnology, and biochemistry · 18 Jun 2026 PMID 42315484
By study type
Observational studies and case reports (5)
- Temporary Mesocaval Bypass During Pancreaticoduodenectomy for Pancreatic Cancer With Portal Vein Occlusion: A Case Report. Anticancer research · 1 Oct 2026 PMID 42823171
- Well-differentiated SMARCB1-deficient Pancreatic Malignancy With Indolent Liver Metastases. Anticancer research · 1 Oct 2026 PMID 42823145
- Association between cachexia-associated diagnoses, health care resource utilization, and costs in patients with pancreatic, lung, and colorectal cancers: A US insurance claims database analysis. Journal of managed care & specialty pharmacy · 29 Sept 2026 PMID 42808542
- Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network. Journal of gastrointestinal cancer · 16 Sept 2026 PMID 42745130
- Quantitative evaluation of respiratory motion-induced blurring in expiratory-phase CBCT for pancreatic SBRT. Journal of applied clinical medical physics · 31 Jul 2026 PMID 42535485
Human data, design not indexed (1)
- Disease-specific gut microbial signatures generate model-derived cancer probability scores through targeted fecal qPCR profiling. Bioscience, biotechnology, and biochemistry · 18 Jun 2026 PMID 42315484
Preclinical: animal, cell and lab studies (1)
- Microencapsulated tumor organoids maintain drug sensitivity stratification. Lab on a chip · 5 Oct 2026 PMID 42831367
Unclassified: not yet indexed with MeSH (2)
- Glycosylated hypoxic tumour-derived extracellular vesicles as a targeted siRNA delivery system to remodel the immunosuppressive microenvironment in pancreatic cancer. Journal of drug targeting · 24 Oct 2026 PMID 42925099
- Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data. PLoS computational biology · 10 Sept 2026 PMID 42721202
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-10-20. Drafted by language models from published abstracts; not medical advice.